Other GLP-1 receptor agonists Healthcare providers advise that semaglutide should not be used with other GLP-1 receptor agonists like tirzepatide (Mounjaro), liraglutide (Victoza), and dulaglutide (Trulicity)
However, with inverse variance weighted Mendelian randomization, no causal relationship between serum vitamin C levels and MASLD risk was observed (OR = 0.82, p = 0.502)
Conversely, some patients may experience constipation, which can result from the delayed gastric emptying and altered intestinal motility
This could lead to issues like bacterial contamination, impurities, and the use of lower-grade ingredients
Compounded Medications: Regulatory Framework According to MEDVi's terms: "Compounded medications are not reviewed or approved by the FDA as finished products